Polymer-lipid hybrid theranostic nanoparticles co-delivering ultrasmall superparamagnetic iron oxide and paclitaxel for targeted magnetic resonance imaging and therapy in atherosclerotic plaque

Journal of Biomedical Nanotechnology

Volumn 12, Issue 6, 2016, Pages 1245-1257

  Dong, Yinmei ^a   Chen, Huaiwen ^b   Chen, Chao ^a   Zhang, Xuefeng ^a   Tian, Xia ^a   Zhang, Yingying ^b   Shi, Zhang ^a   Liu, Qi ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerotic plaque; Magnetic nanoparticles; Paclitaxel; Theranostics

Indexed keywords

COLLAGEN; CONJUGATED POLYMERS; ENCAPSULATION; IRON OXIDES; MACROPHAGES; MAGNETISM; NANOMAGNETICS; NANOPARTICLES; PARTICLE SIZE; SUPERPARAMAGNETISM;

ATHEROSCLEROTIC PLAQUE; ENCAPSULATION EFFICIENCY; MAGNETIC NANO-PARTICLES; NANOPRECIPITATION METHOD; PACLITAXEL; SIMULTANEOUS IMAGING; THERANOSTICS; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

MAGNETIC RESONANCE IMAGING;

C11 POLYPEPTIDE; COLLAGEN TYPE 4; IRON; MATRIGEL; PACLITAXEL; POLYPEPTIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; DEXTRAN; FERUMOXTRAN-10; LIPID; MAGNETITE NANOPARTICLE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PERITONEUM MACROPHAGE; THERANOSTIC NANOMEDICINE; THERAPY EFFECT; ANIMAL; CHEMISTRY; METABOLISM; PROCEDURES; RABBIT;

ANIMALS; DEXTRANS; LIPIDS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; PACLITAXEL; PLAQUE, ATHEROSCLEROTIC; POLYMERS; RABBITS; THERANOSTIC NANOMEDICINE;

EID: 84964723087     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2016.2239     Document Type: Article

References (32)

1. C. Weber and H. Noels, Atherosclerosis: Current pathogenesis and therapeutic options. Nat. Med. 17, 1410 (2011).
2. P. Libby, Y. Okamoto, V. Z. Rocha, and E. Folco, Inflammation in atherosclerosis: Transition from theory to practice. Circ. J. 74, 213 (2010).
3. T. Y. Tang, K. H. Muller, M. J. Graves, Z. Y. Li, S. R. Walsh, V. Young, U. Sadat, S. P. Howarth, and J. H. Gillard, Iron oxide particles for atheroma imaging. Arterioscler Thromb. Vasc. Biol. 29, 1001 (2009).
4. L. M. Biasucci, M. Leo, and G. L. Maria, Local and systemic mechanisms of plaque rupture. Angiology 59, 73S (2008).
5. S. A. Schmitz, M. Taupitz, S. Wagner, K. J. Wolf, D. Beyersdorff, and B. Hamm, Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14, 355 (2001).
6. I. Kawahara, M. Nakamoto, N. Kitagawa, K. Tsutsumi, I. Nagata, M. Morikawa, and T. Hayashi, Potential of magnetic resonance plaque imaging using superparamagnetic particles of iron oxide for the detection of carotid plaque. Neurol. Med. Chir. (Tokyo) 48, 157 (2008).
7. J. M. Richards, C. A. Shaw, N. N. Lang, M. C. Williams, S. I. Semple, T. J. MacGillivray, C. Gray, J. H. Crawford, S. R. Alam, A. P. Atkinson, E. K. Forrest, C. Bienek, N. L. Mills, A. Burdess, K. Dhaliwal, A. J. Simpson, W. A. Wallace, A. T. Hill, P. H. Roddie, G. McKillop, T. A. Connolly, G. Z. Feuerstein, G. R. Barclay, M. L. Turner, and D. E. Newby, In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: Feasibility and safety in humans. Circ. Cardiovasc. Imaging 5, 509 (2012).
8. M. F. Bellin, J. A. Webb, A. J. Van Der Molen, H. S. Thomsen, and S. K. Morcos, Members of contrast media safety committee of european society of urogenital radiology (ESUR). Safety of MR liver specific contrast media. Eur. Radiol. 15, 1607 (2005).
9. E. Ansciaux, C. Burtea, S. Laurent, D. Crombez, D. Nonclercq, E. L. Vander, and R. N. Muller, In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: Toward earlier diagnosis of Alzheimer's disease by molecular imaging. Contrast Media Mol. Imaging (2014) doi: 10.1002/cmmi.1626.
10. Y. He, W. Song, J. Lei, Z. Li, J. Cao, S. Huang, J. Meng, H. Xu, Z. Jin, and H. Xue, Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic cancer cell lines. Acta Radiol. 53, 1049 (2012).
11. X. Zhao, H. Zhao, Z. Chen, and M. Lan, Ultrasmall superparamagnetic iron oxide nanoparticles for magnetic resonance imaging contrast agent. J. Nanosci. Nanotechnol. 14, 210 (2014).
12. S. Lee, J. Xie, and X. Chen, Peptide-based probes for targeted molecular imaging. Biochemistry 49, 1364 (2010).
13. H. C. Stary, A. B. Chandler, R. E. Dinsmore, V. Fuster, S. Glagov, W. J. Insull, M. E. Rosenfeld, C. J. Schwartz, W. D. Wagner, and R. W. Wissler, A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Circulation 92, 1355 (1995).
14. W. Chen, D. P. Cormode, Y. Vengrenyuk, B. Herranz, J. E. Feig, A. Klink, W. J. Mulder, E. A. Fisher, and Z. A. Fayad, Collagenspecific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging 6, 373 (2013).
15. K. A. Radermacher, N. Beghein, S. Boutry, S. Laurent, E. L. Vander, R. N. Muller, B. F. Jordan, and B. Gallez, In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: A multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol. 44, 398 (2009).
16. K. A. Kelly, J. R. Allport, A. Tsourkas, V. R. Shinde-Patil, L. Josephson, and R. Weissleder, Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327 (2005).
17. R. Kalluri, Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422 (2003).
18. J. Xu, D. Rodriguez, E. Petitclerc, J. J. Kim, M. Hangai, Y. S. Moon, G. E. Davis, and P. C. Brooks, Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154, 1069 (2001).
19. J. M. Chan, L. F. Zhang, and R. Tong, Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. USA 107, 2213 (2010).
20. R. Virmani, A. Burke, and A. Farb, Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. Eur. Heart J. 19, 678 (1998).
21. W. Chen, E. Vucic, E. Leupold, W. J. Mulder, D. P. Cormode, K. C. Briley-Saebo, A. Barazza, E. A. Fisher, M. Dathe, and Z. A. Fayad, Incorporation of an apoE-derived lipopeptide in highdensity lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3, 233 (2008).
22. S. Katsuda, Y. Okada, T. Minamoto, Y. Oda, Y. Matsui, and I. Nakanishi, Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb. 12, 494 (1992).
23. N. Ahmed, H. Fessi, and A. Elaissari, Theranostic applications of nanoparticles in cancer. Drug Discov. Today. 17, 928 (2012).
24. O. Taratula, O. Garbuzenko, R. Savla, Y. A. Wang, H. He, and T. Minko, Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticlesdendrimer complexes. Curr. Drug Deliv. 8, 59 (2011).
25. N. Ahmed, M. Michelin-Jamois, H. Fessi, and A. Elaissari, Modified double emulsion process as a new route to prepare submicron biodegradable magnetic/polycaprolactone particles for in vivo theranostics. Soft Matter. 8, 2554 (2012).
26. J. Gao, Y. Xia, H. W. Chen, J. Song, W. Li, W. Qian, H. Wang, J. Dai, and Y. Guo, Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond.) 9, 279 (2014).
27. L. O. Jensen, P. Thayssen, K. E. Pedersen, S. Stender, and T. Haghfelt, Regression of coronary atherosclerosis by simvastatin. Circulation 110, 265 (2004).
28. R. C. Maranhão, E. R. Tavares, A. F. Padoveze, C. J. Valduga, D. G. Rodrigues, and M. D. Pereira, Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis 197, 959 (2008).
29. N. Sun, D. X. Chen, H. C. Gu, and X. L. Wang, Experimental study on T2 relaxation time of protons in water suspensions of iron-oxide nanoparticles: Waiting time dependence. J. Magn. Magn. Mater. 321, 2971 (2009).
30. K. Tsuchiya, N. Nitta, A. Sonoda, H. Otani, M. Takahashi, K. Murata, M. Shiomi, Y. Tabata, and S. Nohara, Atherosclerotic imaging using 4 types of superparamagnetic iron oxides: New possibilities for mannan-coated particles. Eur. J. Radiol. 82, 1919 (2013).
31. S. Tan, X. Li, Y. Guo, and Z. Zhang, Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale 5, 860 (2013).
32. J. Gao, S. S. Feng, and Y. J. Guo, Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond.) 5, 1141 (2010).